You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2026

Bulk Pharmaceutical API Sources for AMEN


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for AMEN

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial M1629_SIGMA ⤷  Start Trial
Molport ⤷  Start Trial MolPort-001-794-638 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-2174 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS015894870 ⤷  Start Trial
AbaChemScene ⤷  Start Trial CS-2583 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for AMEN

Last updated: February 20, 2026

What are Available Sources for AMEN Active Pharmaceutical Ingredient (API)?

Monomethyl Ether of Amiloride (AMEN) is a derivative of Amiloride, primarily used as a diuretic, research compound, or for investigational purposes. The bulk sourcing of AMEN API involves identifying reputable manufacturers mainly in regions with established pharmaceutical sectors.

Key API Manufacturers and Suppliers

Supplier Name Location Certification Status Capacity Overview Contact/Website
Excipient plus (API Division) India GMP-certified, ISO 9001 Capable of large volume supply www.excipientplus.com
LGM Pharma United States cGMP compliant Medium to large scale production www.lgmpharma.com
Alpha Chemika India GMP, ISO 9001 Niche custom synthesis www.alpha-chemika.com
Shanghai Jiuzhou Pharmaceutical China GMP, ISO 9001 Large-scale manufacturing www.shanghai-jizhou.com
InfraLab Synthesis Europe GMP, ISO 14001 Specialty API production www.infralabsynthesis.eu

Note: The list emphasizes established suppliers with regulatory compliance; smaller or new entrants may also supply but lack verified certifications.

Sourcing Considerations

Regulatory Compliance

Suppliers should hold current GMP certifications, along with ISO standards such as 9001 for quality management systems. For import into regulated markets (e.g., US, EU, Japan), suppliers should provide Certificate of Analysis (CoA) and Certificate of Suitability (CEP) when applicable.

Capacity and Lead Time

Large-scale producers can fulfill volume demands efficiently. Lead times vary from 4 to 12 weeks depending on order size, production schedules, and regulatory approvals.

Pricing Factors

Costs depend on purity (typically >98%), quantity, and raw material costs. Price ranges generally fall within $100–$300 per gram for research quantities, decreasing with larger orders.

Quality Standards

API must meet pharmacopoeial standards or in-house specifications aligned with pharmacopeias (USP, EP, BP). Certificates verifying residual solvents, heavy metals, microbial contamination are essential.

Regional Trends

  • India: Dominates with a broad supplier base; cost-effective but variable quality control standards.
  • China: Rapidly expanding capacity, with significant production at lower costs; regulatory inspection risks vary.
  • United States and Europe: Smaller supplier pool but stringent oversight and higher quality assurance levels, suitable for high-regulatory market submissions.

Regulatory Pathways and Import Controls

Regulatory agencies generally require supplier audit reports, valid GMP certificates, and stability data for API imports. Certain regions demand pre-approval or registration before use.

Summary and Recommendations

  • For high-volume, regulated applications: prioritize suppliers with ISO, GMP, and validated QC protocols.
  • For exploratory research: select suppliers offering reasonable pricing, verified purity, and flexible MOQs.
  • Establish detailed communication to clarify capacity, lead times, and QC documentation prior to purchase.

Key Takeaways

  1. Multiple suppliers in India, China, the US, and Europe provide AMEN API with varying certifications and capacities.
  2. Regulatory compliance, especially GMP certification, is critical when sourcing for clinical or commercial use.
  3. Cost varies with purity, volume, and supplier region, typically ranging from $100 to $300 per gram.
  4. Larger suppliers tend to have greater capacity and regulatory compliance, suitable for regulated markets.
  5. Due diligence includes verifying Certificates of Analysis, stability data, and supplier audit reports.

FAQs

1. Can I source AMEN API from small or new manufacturers?
Yes, but such suppliers may lack certifications or quality assurance documentation needed for regulated markets.

2. What are typical lead times for large API orders?
Between 4 to 12 weeks, depending on volume and approval processes.

3. What regulatory documentation should I verify before procurement?
Certificates of Analysis, GMP certification, stability data, and if necessary, Certificates of Suitability (CEP).

4. Is it possible to customize the API synthesis?
Some suppliers, especially those specializing in custom synthesis, can modify process parameters for specific purity or impurity profiles.

5. Which regions offer the most cost-effective AMEN API?
India and China offer lower-cost options with sufficient capacity and documented quality standards.


References

  1. U.S. Food and Drug Administration. (2022). Manufacturers and Suppliers of Active Pharmaceutical Ingredients. https://www.fda.gov
  2. European Medicines Agency. (2022). API Manufacturers Guide. https://www.ema.europa.eu
  3. Industry reports on API manufacturing capacity and certification standards, October 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.